Hims & Hers (NYSE: HIMS) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
25m
With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...
Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback